A detailed history of Mariner, LLC transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Mariner, LLC holds 56,334 shares of AMLX stock, worth $228,152. This represents 0.0% of its overall portfolio holdings.

Number of Shares
56,334
Previous 57,539 2.09%
Holding current value
$228,152
Previous $109,000 66.97%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$1.65 - $3.24 $1,988 - $3,904
-1,205 Reduced 2.09%
56,334 $182,000
Q2 2024

Aug 13, 2024

BUY
$1.62 - $2.71 $13,399 - $22,414
8,271 Added 16.79%
57,539 $109,000
Q1 2024

May 15, 2024

SELL
$2.71 - $19.57 $441 - $3,189
-163 Reduced 0.33%
49,268 $139,000
Q4 2023

Feb 14, 2024

BUY
$12.07 - $18.46 $9,728 - $14,878
806 Added 1.66%
49,431 $727,000
Q3 2023

Nov 13, 2023

SELL
$18.08 - $23.45 $307 - $398
-17 Reduced 0.03%
48,625 $890,000
Q2 2023

Aug 11, 2023

BUY
$20.98 - $31.42 $776 - $1,162
37 Added 0.08%
48,642 $1.05 Million
Q1 2023

May 12, 2023

BUY
$27.71 - $40.93 $294,113 - $434,431
10,614 Added 27.94%
48,605 $1.43 Million
Q4 2022

Feb 14, 2023

BUY
$29.75 - $39.26 $1.13 Million - $1.49 Million
37,991 New
37,991 $1.4 Million

Others Institutions Holding AMLX

About Amylyx Pharmaceuticals, Inc.


  • Ticker AMLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,533,200
  • Market Cap $237M
  • Description
  • Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...
More about AMLX
Track This Portfolio

Track Mariner, LLC Portfolio

Follow Mariner, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mariner, LLC with notifications on news.